Optimal Antiplatelet Therapy In NSTE-ACS: Results From A Novel Crowdsourcing Survey


The choice and duration of antiplatelet therapy in NSTE-ACS undergoing PCI is complex and is a hotly debated topic – particularly amongst patients at high bleeding risk. To gain insight into the real-world practices of a global cross-section of cardiologists, Radcliffe Medical Education, in partnership with the International Society of Cardiovascular Pharmacotherapy (ISCP), undertook a novel crowdsourcing project to capture their prevailing beliefs and practices in antiplatelet treatment, in patients at high bleeding risk.

We reported our findings in a paper recently published in the International Journal of Cardiology and are delighted to now bring you a roundtable discussion, featuring members of the steering committee, to further explain the project, the main findings, and the potential implications for future research.

To view the article please click here

This project was made possible by an unrestricted educational grant from AstraZeneca.

Juan Carlos Kaski – St George’s University of London

  • Welcome and introductions

Deepak Bhatt – Brigham and Women’s Hospital, Boston and Harvard Medical School

  • Unmet needs in high bleeding risk patients
  • Rationale for the research
  • Demographics

Felicita Andreotti – Gemelli IRCCS Hospital and Catholic University, Rome

  • Overarching trends
  • Observations of interest

Dominick J Angiolillo – University of Florida College of Medicine

  • Clinical implications
  • Future applications

To view the questions asked in the survey please click to download slides

To view the article please click here

Optimal Antiplatelet Therapy In NSTE-ACS: Results From A Novel Crowdsourcing Survey

Performed by

Prof Juan Carlos Kaski

Chairman

Performed by

Prof Deepak Bhatt

Co-Chairman

Prof Felicita Andreotti
Prof Dominick J Angiolillo

Panellists